Cyclerion Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Cyclerion Therapeutics'in gelir ve kazançlarının sırasıyla 162.1% ve 49.5% yıllık düşüş göstermesi beklenirken, EPS'nin büyümesi beklenmektedir.

Anahtar bilgiler

-49.5%

Kazanç büyüme oranı

22.11%

EPS büyüme oranı

Biotechs kazanç büyümesi	25.5%
Gelir büyüme oranı	-162.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	23 Feb 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Seeking Alpha • Oct 06

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration. Cyclerion has upcoming phase 2 data coming out in H12022 that will be a major inflection point to potentially open up new opportunities for the distressed company. As a result, the company is one to monitor over the next few months and wait to potentially buy the stock after new clinical data is reported.

Seeking Alpha • Jun 21

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

After two candidate failures over the past two years, Cyclerion Therapeutics, Inc. is pinning its hopes on CNS therapy CY6463. The soluble guanylate cyclase modulator is currently undergoing mid-stage evaluation for one CNS indication and should enter a Phase 2 study for another in 2021. With a small market cap and no clinical data due until YE21, yet significant insider buying from the CEO, this busted IPO merited a deeper dive. A full investment analysis is provided in the paragraphs below.

Analiz Makalesi • Mar 09

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

Analiz Makalesi • Jan 28

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

A look at the shareholders of Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) can tell us which group is most powerful...

Analiz Makalesi • Dec 20

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

The last three months have been tough on Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) shareholders, who have seen the...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:CYCN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	N/A	-15	N/A	N/A	1
12/31/2026	N/A	-12	N/A	N/A	1
3/31/2026	2	-5	-4	-4	N/A
12/31/2025	2	-4	-3	-3	N/A
9/30/2025	3	-2	-1	-1	N/A
6/30/2025	2	-2	-3	-3	N/A
3/31/2025	2	-3	-3	-3	N/A
12/31/2024	2	-3	-4	-4	N/A
9/30/2024	0	-5	-6	-6	N/A
6/30/2024	N/A	-10	-11	-11	N/A
3/31/2024	N/A	-11	-17	-17	N/A
12/31/2023	N/A	-13	-21	-21	N/A
9/30/2023	N/A	-15	-27	-27	N/A
6/30/2023	-1	3	-30	-30	N/A
3/31/2023	0	-8	-34	-34	N/A
12/31/2022	0	-18	-41	-41	N/A
9/30/2022	1	-25	-42	-42	N/A
6/30/2022	2	-48	-40	-40	N/A
3/31/2022	5	-51	-35	-35	N/A
12/31/2021	4	-52	-37	-37	N/A
9/30/2021	4	-60	-42	-42	N/A
6/30/2021	4	-68	-49	-49	N/A
3/31/2021	1	-71	-58	-58	N/A
12/31/2020	2	-78	-74	-72	N/A
9/30/2020	4	-85	-82	-81	N/A
6/30/2020	5	-93	-92	-89	N/A
3/31/2020	6	-106	-104	-97	N/A
12/31/2019	5	-123	N/A	-102	N/A
9/30/2019	3	-128	N/A	-103	N/A
6/30/2019	2	-130	N/A	-105	N/A
3/31/2019	N/A	-127	N/A	-105	N/A
12/31/2018	N/A	-115	N/A	-98	N/A
9/30/2018	N/A	-112	N/A	-100	N/A
6/30/2018	N/A	-108	N/A	-95	N/A
3/31/2018	N/A	-99	N/A	-90	N/A
12/31/2017	N/A	-94	N/A	-81	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CYCN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: CYCN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: CYCN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: CYCN gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: CYCN gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CYCN 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/20 18:20
Gün Sonu Hisse Fiyatı	2026/05/20 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Cyclerion Therapeutics, Inc. 3 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Pete Stavropoulos	Cantor Fitzgerald & Co.
Joon So Lee	Truist Securities
David Bautz	Zacks Small-Cap Research

Cyclerion Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased to US$4.00

Consensus revenue estimates fall by 54%

Consensus forecasts updated

Price target increased to US$10.50

Consensus revenue estimates fall by 49%

Recent updates

First quarter 2026 earnings released: US$0.76 loss per share (vs US$0.56 loss in 1Q 2025)

New major risk - Financial position

Korsana Biosciences, Inc. entered into a definitive merger agreement to acquire Cyclerion Therapeutics, Inc. (NasdaqCM:CYCN) for approximately $270 million in a reverse merger transaction.

High number of new and inexperienced directors

Cyclerion Therapeutics, Inc. Receives Positive Written Regulatory Feedback and Responses from the FDA on CYC-126's Phase 2 POC study in TRD and Its Path to Potential Regulatory Approval

New major risk - Revenue and earnings growth

Cyclerion Therapeutics, Inc. Announces Progress Toward Initiating Phase 2 Proof-Of-Concept Study for CYC-126 in Treatment-Resistant Depression

New major risk - Shareholder dilution

New major risk - Financial position

New minor risk - Shareholder dilution

Cyclerion Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

New major risk - Financial position

Cyclerion Therapeutics, Inc., Annual General Meeting, Jun 16, 2025

Cyclerion Therapeutics, Inc. announced that it has received $1.374995 million in funding from J. Wood Capital Advisors LLC, Polaris Founders Capital and other investors

Cyclerion Therapeutics, Inc. Announces Promotion of Regina Graul to Chief Executive Officer

Cyclerion Therapeutics, Inc., Annual General Meeting, Jun 14, 2024

Cyclerion Therapeutics, Inc. Appoints Regina Graul as President

Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments

Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director

Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer

New major risk - Financial position

First half 2023 earnings released: US$5.00 loss per share (vs US$12.14 loss in 1H 2022)

New major risk - Market cap size

Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding

High number of new and inexperienced directors

J & W Cycles, Inc. signed a definitive agreement to acquire sGC Stimulator Assets of Cyclerion Therapeutics, Inc. for $8 million.

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.30 loss in 1Q 2022)

Full year 2022 earnings released: US$1.01 loss per share (vs US$1.32 loss in FY 2021)

Cyclerion Therapeutics Announces an Extended Listing Compliance Period

Price target decreased to US$4.00

Third quarter 2022 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021)

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Consensus revenue estimates fall by 54%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia

Cyclerion Therapeutics, Inc. Announces Appointment of Steven E. Hyman, M.D., to its Board of Directors

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Cyclerion Therapeutics, Inc. Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for Cy6463 in Melas Patients At Umdf Mitochondrial Medicine 2022 Symposium

Cyclerion Therapeutics Receives a Deficiency Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price Requirement

High number of new directors

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cyclerion Therapeutics, Inc. Announces CY6463 Clinical Pipeline Progress

Price target increased to US$10.50

High number of new directors

Consensus revenue estimates fall by 49%

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Full year 2021 earnings: EPS and revenues miss analyst expectations

Cyclerion Therapeutics, Inc. Announces CY6463 Clinical Pipeline Updates

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology

Third quarter 2021 earnings released: US$0.26 loss per share (vs US$0.59 loss in 3Q 2020)

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Cyclerion Therapeutics, Inc Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Independent Director Kevin Churchwell has left the company

Second quarter 2021 earnings released: US$0.45 loss per share (vs US$0.70 loss in 2Q 2020)

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021

Cyclerion Therapeutics, Inc.(NasdaqGS:CYCN) dropped from Russell 3000E Value Index

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Cyclerion Therapeutics, Inc. announced that it has received $17.896283 million in funding from EcoR1 Capital, LLC, Slate Path Capital LP, MFN Partners Management, LP, The Invus Group, LLC, Lincoln Park Capital, LLC, Polaris Partners

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

CEO & Director recently bought US$1.7m worth of stock

First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.73 loss in 1Q 2020)

Cyclerion Therapeutics, Inc. Provides Clinical Updates for its CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 in Alzheimer's Disease with Vascular Pathology and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes

Cyclerion Therapeutics, Inc. Announces Departure of Christopher Wright as Chief Medical Officer

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Full year 2020 earnings released: US$2.56 loss per share (vs US$4.49 loss in FY 2019)

Earnings beat expectations

New 90-day high: US$3.61